1541 — ImmuneOnco Biopharmaceuticals Shanghai Balance Sheet
0.000.00%
Last trade - 00:00- HK$3.05bn
- HK$2.44bn
- CNY74.15m
Annual balance sheet for ImmuneOnco Biopharmaceuticals Shanghai, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 668 | 635 | 609 | 752 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 0.034 | 0.991 | 0.948 | 0.016 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 704 | 652 | 687 | 868 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 164 | 174 | 159 | 47.7 |
| Long Term Notes Receivable | ||||
| Other Long Term Assets | ||||
| Total Assets | 893 | 840 | 875 | 922 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Current Portion of Long Term Debt / Capital Leases | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 2,478 | 51.7 | 116 | 215 |
| Long Term Debt | ||||
| Capital Lease Obligations | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Minority Interest | ||||
| Total Liabilities | 2,491 | 60.8 | 126 | 243 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | -1,598 | 779 | 748 | 679 |
| Total Liabilities & Shareholders' Equity | 893 | 840 | 875 | 922 |
| Total Common Shares Outstanding |